[Serum amyloid a protein concentrations in patients with familial Mediterranean fever].
the determination of serum amyloid A (SAA) protein concentrations in FMF patients: the colchicine-resistant patients and the patients responded to the different doses of colchicine, and estimation of the risk of the amyloidosis development in these patients. SAA concentration was measured in 58 FMF patients: 23 colchicine-resistant patients without amyloidosis and 35 patients responded to the different doses of colchicine also without amyloidosis as a group of comparison. Serum SAA concentration was measured by ELISA (Enzyme Linked-Immuno-Sorbent-Assay) method using "ANOGEN" kit (Canada). Serum SAA concentration was the same in both groups of the patients: colchicine-resistant patients and patients responded to the different doses of colchicine. The findings of our study indicate that the risk of the amyloidosis development is the same in colchicine-resistant patients and patients responded to the different doses of colchicine.
Z T
ZT
Dzhndoian
D000328:Adult; D000686:Amyloidosis / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D054316:Biomarkers, Pharmacological / Q000032:analysis / Q000378:metabolism*; D003078:Colchicine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D010505:Familial Mediterranean Fever / Q000097:blood* / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D000685:Serum Amyloid A Protein / Q000032:analysis / Q000378:metabolism*
D054316:Biomarkers, Pharmacological; D000685:Serum Amyloid A Protein; D003078:Colchicine